Recombinant Canine CTLA-4 Fc Chimera, CF

R&D Systems, part of Bio-Techne | Catalog # 10954-CT

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
10954-CT-100
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

CHO

Accession #

NP_001003106.1

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

View all CTLA-4 Proteins and Enzymes »

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived canine CTLA-4 protein
Lys36-Asp161

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Lys36

Predicted Molecular Mass

40 kDa

SDS-PAGE

48-60 kDa, under reducing conditions.

Activity

Measured by its ability to inhibit IL-2 secretion by stimulated Jurkat human acute T cell leukemia cells. Linsley, P.S. et al. (1991) J. Exp. Med. 174:561.
The ED50 for this effect is 30.0-300 ng/mL.

Scientific Data Images for Recombinant Canine CTLA-4 Fc Chimera, CF

Recombinant Canine CTLA‑4 Fc Chimera Protein Bioactivity.

Recombinant Canine CTLA-4 Fc Chimera Protein (Catalog # 10954-CT) inhibits IL-2 secretion by stimulated Jurkat human acute T cell leukemia cells. The ED50 for this effect is 30.0-300 ng/mL

Recombinant Canine CTLA-4 Fc Chimera Protein SDS-PAGE.

2 μg/lane of Recombinant Canine CTLA-4 Fc Chimera Protein (Catalog # 10954-CT) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 48-60 kDa and 100-120 kDa, respectively.

Formulation, Preparation and Storage

10954-CT
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CTLA-4

CTLA-4 (cytotoxic T-lymphocyte-4, designated CD152), is a type I transmembrane T cell inhibitory molecule that is a member of the Ig superfamily (1, 2). Canine CTLA-4 cDNA A encodes 223 amino acids (aa) including a 35 aa signal sequence, a 126 aa extracellular domain (ECD) with one Ig-like V-type domain, a 21 aa transmembrane (TM) sequence, and a 41 aa cytoplasmic sequence.Within the ECD, canine CTLA-4 shares 84%, 69%, and 71% aa sequence identity with human, mouse and rat CTLA-4 respectively. CD28, which is structurally related to CTLA-4, is constitutively expressed on naïve T cells and promotes T cell activation when engaged by B7-2 on antigen-presenting cells (APC) within the immunological synapse (IS) (1, 3, 4). In contrast, CTLA-4 is recruited from intracellular vesicles to the IS beginning 1, 2 days after T cell activation (2, 3, 4). It forms a linear lattice with B7‑1 on APC, inducing negative regulatory signals and ending T cell activation (5). Abatacept, a therapeutic human CTLA-4-Ig fusion protein (trade name Orencia), competes with CD28 for B7-1 and B7-2 binding and has been used to antagonize T cell activation in autoimmune conditions and to enhance transplant survival (6). Mice deleted for CTLA-4 show no abnormalities until after birth, but then develop lethal autoimmune reactions due to continued T cell activation and poor control by regulatory T cells, which constitutively express CTLA-4 in wild-type mice and humans (7-9).

References

  1. Harper, K. et al. (1991) J. Immunol. 147:1037.
  2. Teft, W.A. et al. (2006) Annu. Rev. Immunol. 24:65.
  3. Pentcheva-Hoang, T. et al. (2004) Immunity 21:401.
  4. Jansson, A. et al. (2005) J. Immunol 175:1575.
  5. Darlington, P.J. et al. (2005) J. Immunol. 175:996.
  6. Platt, A.M. et al. (2010) J. Immunol. 185:1558.
  7. Wing, K. et al. (2008) Science 322:271.
  8. Friedline, R.H. et al. (2009) J. Exp. Med. 206:421.
  9. Jain, N. et al. (2010) Proc. Natl. Acad. Sci. U.S.A. 107:1524.

Long Name

Cytotoxic T-lymphocyte-associated Molecule 4

Alternate Names

CD152, CTLA4

Entrez Gene IDs

1493 (Human); 12477 (Mouse); 403696 (Canine); 102115124 (Cynomolgus Monkey)

Gene Symbol

CTLA4

UniProt

NP_001003106.1

Additional CTLA-4 Products

Product Documents for Recombinant Canine CTLA-4 Fc Chimera, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Canine CTLA-4 Fc Chimera, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.